Loading
Gotistobart is an experimental monoclonal antibody from OncoC4 in phase 3 trials for non-small-cell lung cancer, melanoma and head and neck squamous cell carcinoma, aimed at CTLA-4.
Gotistobart (ONC-392, BNT316) is a monoclonal antibody developed by OncoC4. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: CTLA-4 checkpoint inhibition, in some regimens combined with pembrolizumab or Pluvicto. ClinicalTrials.gov describes the intervention as: Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors), in non-small-cell lung cancer, melanoma, head and neck squamous cell carcinoma, renal cell carcinoma and colorectal cancer. The largest, NCT04140526, plans to enrol 733 participants with primary completion was scheduled for 2026-06-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
CTLA-4 checkpoint inhibition, in some regimens combined with pembrolizumab or Pluvicto. Connects to CTLA-4.
1.Gotistobart binds CTLA-4.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Gotistobart" OR ABSTRACT:"Gotistobart" OR TITLE:"ONC-392" OR ABSTRACT:"ONC-392" OR TITLE:"BNT316" OR ABSTRACT:"BNT316" OR TITLE:"A humanized anti-CTLA4 IgG1 monoclonal antibody" OR ABSTRACT:"A humanized anti-CTLA4 IgG1 monoclonal antibody") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Gotistobart, not a curated reading list.
Shares CTLA-4, Renal cell carcinoma, Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Ovarian cancer and the tag pipeline.
Shares Renal cell carcinoma, Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Bladder & urothelial cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Oesophageal cancer, Sarcomas (soft tissue, bone, GIST), Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Bladder & urothelial cancer, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, HR-positive / HER2-negative breast cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.